At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 54 enrolled
Drug / intervention
MP-424 +2 moredrug
Likely dose
MP-424 750mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Naïve or Relapsed After Previous Treatment
In Brief
A Phase 3 clinical trial evaluating MP-424, RBV, and 1 other intervention for Chronic Hepatitis C (CHC). Completed, enrolled 54 participants across 1 site.
Detailed Summary
This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C (CHC)
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedDec 2012
Primary CompletionNov 2014
TodayJul 2026
First PostedDec 20, 2012
Enrollment StartDec 1, 2012
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.5 years ago
Interventions
MP-424drug
MP-424: 750mg every 8 hours (q8h) for 12 weeks
RBVdrug
RBV: 600 - 1000 mg/day based on body weight for 24 weeks
PEG-IFN alfa-2adrug
PEG-IFN alfa-2a: 180mcg/week for 24 weeks